Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have ...

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other Tuesday’s worst-performing stocks. Wall Street’s main indices suffered a bloodbath on ...

We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other Tuesday’s worst-performing ...

Tempus AI share price have crashed by over 60% from the YTD high. There are concerns about the company’s growth trajectory. Technicals point to more downside, and then bounce back once the panic ...

Ambry was subsequently acquired by Tempus AI in February 2025 ... From 2016 to 2021, Aaron led Ambry Genetics as CEO and transformed the company into one of the largest hereditary cancer testing ...